Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Menlo Therapeutics
Menlo Therapeutics
A pair of PhIII failures spells last rites for Menlo’s once-promising Merck drug
A pair of PhIII failures spells last rites for Menlo’s once-promising Merck drug
Endpoints
Menlo Therapeutics
clinical trials
serlopitant
Flag link:
Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus
Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus
EP Vantage
Gilead Sciences
Galapagos
filgotinib
ulcerative colitis
Menlo Therapeutics
serlopitant
Flag link:
Peninsula biotech coughs up 40 percent of its value on failed clinical trial
Peninsula biotech coughs up 40 percent of its value on failed clinical trial
Bizjournals.com
clinical trials
IPOs
Menlo Therapeutics
serlopitant
Flag link:
Nasdaq Exec 'Even More Bullish' On Biotech IPOs As New Entries Soar
Nasdaq Exec 'Even More Bullish' On Biotech IPOs As New Entries Soar
Forbes
biotech
NASDAQ
IPOs
ARMO BioSciences
Menlo Therapeutics
Cue Biopharma
Flag link:
In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M
In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M
Endpoints
biotech
IPOs
PureTech
ARMO BioSciences
Menlo Therapeutics
Solid Biosciences
Flag link:
